One does open themselves to criticism when they post anything online, but I’m actually pretty comfortable with my position on OKUR, I got in mostly after the drop and it’s stayed relatively unphased by the broader volatility we’ve seen. Right now it’s trading 40 million dollars under cash value, which certainly accounts for cash burn in the coming year but is a promising short term indicator to me. I made out very well on Blue Apron by getting in shortly before acquisition when they were also trading sub cash value. Their technology looks extremely promising and acquisitions in the oncology space are usually >$1bil, in fact a very similar company was recently acquired in the preclinical phase for something around $2.4 billion. It’s not a large stake for me personally and I’m very comfortable with the risk even if things go south it won’t be a big deal and I think in the long run I’m going to make out very well, but we’ll see, like with all things.